PR Newswire PharmaOriginal article
Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials
Sugammadex InjectionPositive
AI Analysis
Summary
Glenmark Pharmaceuticals launched Sugammadex Injection in two formulations (200 mg/2 mL and 500 mg/5 mL single-dose vials). The product is bioequivalent to the reference formulation.
Outcome Details
Product launch of Sugammadex Injection in 200 mg/2 mL and 500 mg/5 mL formulations
Importance:3/10
Sentiment:
0.30
product launchgenericsugammadexneuromuscular blockade reversal
Read the original article
Published by PR Newswire Pharma on July 28, 2026 6:32 PM